Previous 10 | Next 10 |
Amarin (NASDAQ: AMRN) , a mid-cap pharma company , has long been rumored to be a buyout candidate. The core reason is that the company's prescription omega-3 treatment, Vascepa (icosapent ethyl), hit the mark in a large, placebo-controlled cardiovascular outcomes trial -- a feat no ot...
Amarin 's (NASDAQ: AMRN) shares rocketed higher after a key FDA committee recommended expanding the label of its triglyceride-lowering drug, Vascepa, to include data showing it can reduce the risk of heart attack and stroke. Meanwhile, shares in CRISPR Therapeutics (NASDAQ: CRSP) and part...
Healthcare Pulse Healthcare is at its all-time highs eclipsing the highs recorded a year earlier during the Oct-Nov 2018 period. Of course, if one looks at the broader market which has been recording such all-time highs since the summer of this year, it's understandable to shrug shoulders ...
Introduction Our long thesis on Acasti Pharma, Inc. ( ACST ) is built on two key pillars: 1) We see significant growth in the prescription Omega 3 (Rx OM3) drug market due to the clinically proven benefits of Rx strength OM3 used for treating hypertriglyceridemia ((HTG)), and recently shown ...
Yesterday, Amarin (NASDAQ: AMRN) lost over 10% of its value in response to a rather harsh report by Oppenheimer analyst Leland Gershell. The key issue that triggered this double-digit sell-off appears to be Gershell's uberbearish prediction that Amarin's stock could drop by as much as 70% ...
via TerraPharma More news on: Amarin Corporation plc, Healthcare stocks news, Read more ...
Introduction Before this report, I have written two other Seeking Alpha reports about Acasti Pharma ( ACST ) in 2019, espousing ACST’s profound market opportunity and its leading drug CaPre’s competitive advantages; my first report in June was published when the stock was onl...
Shares of Amarin (NASDAQ: AMRN) fell as much as 16% today after investors digested a bearish report from Wall Street. Oppenheimer analyst Leland Gershell issued a note arguing that Amarin's Vascepa, widely expected to earn broad supplemental approval for reducing major adverse cardiovascula...
Alnylam Pharmaceuticals (NASDAQ: ALNY ) initiated with Outperform rating and $128 (31% upside) price target at Oppenheimer. More news on: Alnylam Pharmaceuticals, Inc., Amarin Corporation plc, CytomX Therapeutics, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
It's a familiar story. A small biotech gets really good news about a promising drug. A big drugmaker with deep pockets is looking for a way to fuel growth. The big drugmaker thinks the small biotech's drug is a good fit with its own lineup and acquires the small biotech. And investors who owned ...
News, Short Squeeze, Breakout and More Instantly...
Amarin Corporation plc Company Name:
AMRN Stock Symbol:
NASDAQ Market:
Amarin Corporation plc Website:
-- Portuguese Ministry of Health approves VAZKEPA® (icosapent ethyl) for national reimbursement to reduce the risk of cardiovascular (CV) events in patients with established cardiovascular disease (CVD) 1 -- -- Approval marks eighth national reimbursement of VAZKEPA®...
DUBLIN and BRIDGEWATER, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin’s senior management team to discuss its second quarter 2024 results followed ...
-- VASCEPA Approved by the National Medical Products Administration (NMPA) To Reduce the Risk of Cardiovascular Events as an Adjunct to Statin Therapy in Adult Patients with Elevated Triglyceride (TG) Levels (≥150 mg/dL) and Other High-Risk Characteristics as Studied in REDUCE-IT -- ...